Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Helmholtz-Zentrum München. (1/17/18). "Press Release: Innovative Antibody Production. Helmholtz Association Funding Spin-off".

Organisations Organisation Helmholtz-Zentrum München, Stem Cell Center
  Group Helmholtz-Gemeinschaft (HGF) (Group)
  Organisation 2 Eximmium (DE)
Products Product antibody technology
  Product 2 MAb production technology
Persons Person Zeidler, Reinhard (Helmholtz 201801 Prof Gene Vectors Research Unit at Helmholtz Zentrum München)
  Person 2 Gärtner, Kathrin (Eximmium)
     


The Helmholtz Association is funding a new Helmholtz Zentrum München spin-off with roughly 115,000 euros. The focus is on a platform technology from Prof. Dr. Reinhard Zeidler, researcher in the Gene Vectors Research Unit (AGV). The technology involves a new method to produce antibodies for diagnostics and therapy.

Monoclonal antibodies have proven their usefulness for treating various diseases in oncology. If they bind to cancer cells, signals are transmitted that ultimately lead to controlled cell death. Antibodies are also quite commonly used in diagnostics. Conventional immunization technologies sometimes fail to produce the right antibodies. Many therapeutically useable target structures, the antigens, are also still unknown. But this could all change soon.

New platform technology uses vesicles

Prof. Dr. Reinhard Zeidler, head of the "Prevention and Immunomodulation" research group in the "Gene Vectors Research Unit" at the Helmholtz Zentrum München, has namely found one solution for both challenges. Zeidler works with extracellular vesicles, which are small bubbles that automatically pinch themselves off from both healthy and cancerous cells. Found in the patient's blood, they consist of a membrane and contain all immunologically important information.

To produce new antibodies, Zeidler and his colleagues of the Monoclonal Antibody Core Facility are working with exactly these vesicles. The method has a number of advantages over classic production with soluble proteins. Vesicles contain almost all cellular proteins in a normal environment. They do not change their spatial structure and consequently they result in especially powerful antibodies. At the same time, it is possible to develop antibodies against previously unknown antigens.

Interesting partner for the pharmaceutical industry

Working with his colleagues, Zeidler has already succeeded in demonstrating the potential that his method offers. A first antibody targeted against malignant brain tumors (Glioblastoma multiforme) will soon be examined in a phase 1 trial on patients. Additional antibodies with diagnostic or therapeutic potential are already in the pipeline. "Our portfolio is a solid basis for a spin-off," Zeidler reports. "Taking center stage are two antibodies that target CD73 and CD276 as checkpoint molecules*.“ The objective is the pre-clinical validation of the antibodies and, in the best case, licensing to an industrial partner. Already-approved therapeutic antibodies are some of the most expensive drugs. "This is why we believe that a spin-off could become an attractive partner for pharmaceutical companies," the scientist adds.

The Helmholtz Association is now promoting the spin-off "Eximmium" through its two programs, Helmholtz Enterprise and Helmholtz Enterprise Plus**. The team headed by Prof. Reinhard Zeidler and Dr. Kathrin Gärtner will receive a total of 115,000 euros over one year. An additional 115,000 euros is coming in the form of co-financing by the Helmholtz Zentrum München itself.

The name "Eximmium" describes both extracellular vesicles and their immunological effect, and is partly derived from the Latin word eximius, which roughly means "extraordinary".


Further Information

* Checkpoint molecules are surface structures on cells in the immune system. In many tumors, these proteins are upregulated and the tumor cells are not attacked by the immune system. Antibodies target these checkpoints, allowing a more intense immune response to be directed at the tumor.

** Helmholtz Enterprise (HE) and Helmholtz Enterprise Plus (HE Plus) form the internal program for spin-offs from the Helmholtz Association. In the last ten years, more than 100 start-up ventures have profited from the initiative (as of the end of 2016). 70 of these projects were successfully set up, and more than 80 percent of these are still active on the market.


As German Research Center for Environmental Health, Helmholtz Zentrum München pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum München has about 2,300 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum München is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 37,000 staff members.

The Research Unit Gene Vectors studies EBV's molecular functions to understand how the virus contributes to different types of disease. The scientists analyse the immune system of virus carriers to find out how EBV and other herpes viruses are kept in check, and why immune control has failed in patients with disease. They also investigate the origins of cancers of the immune system - lymphoma and leukaemia. Their ultimate goal is to develop new drugs, vaccines and cell-based therapies in order to efficiently treat or – preferentially – prevent infectious diseases and cancer.


Contact for the media

Communication Department

Helmholtz Zentrum München -
Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Ingolstädter Landstraße 1
85764 Neuherberg
Germany
Tel. +49 89 3187-2238
E-mail


Scientific Contact

Prof. Dr. Reinhard Zeidler
Helmholtz Zentrum München - German Research Center for Environmental Health
Research Unit Gene Vectors
Marchioninistraße 25
81377 München
Tel. +49 89 3187 1401
E-mail

Dr. Stanimira Rohmer-Strohbach
Helmholtz Zentrum München - German Research Center for Environmental Health
Innovation Management Department
Ingolstädter Landstr. 1
85764 Neuherberg
Tel. +49 89 3187 4273
E-mail

   
Record changed: 2018-01-27

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Helmholtz-Gemeinschaft (HGF) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px